Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound

Bioanalysis. 2021 Dec;13(23):1761-1777. doi: 10.4155/bio-2021-0194. Epub 2021 Nov 15.

Abstract

Aim: ZY-19489 is a new antimalarial drug candidate and selective LC-MS/MS method was established for estimation of ZY-19489 and its metabolite in human plasma. Materials & methods: LLE was employed for extraction, mass spectrometric quantification performed using positive ionization mode and DCP-IMP was used as an internal standard. The chromatographic separation was achieved using mobile phase 5 mM ammonium formate in water and 0.1% v/v ammonia solution in methanol:acetonitrile (90:10% v/v) and column Agilent Zorbex Extended C18, 3.5 μm, 100 × 4.6 mm with a 6-min run time. Results: The calibration curve of ZY-19489 was linear over range 1-500 ng/ml and 2-200 ng/ml for metabolite. Assay was reproducible, selective and devoid of matrix effect. Conclusion: The validated assay was implemented for clinical sample analysis derived from healthy human subjects and parasitemia-induced subjects.

Keywords: LC–MS/MS; ZY-19489; ZY-20486; human plasma; method validation.

MeSH terms

  • Antimalarials* / blood
  • Antimalarials* / metabolism
  • Antimalarials* / standards
  • Calibration
  • Chromatography, High Pressure Liquid* / standards
  • Half-Life
  • Humans
  • Reproducibility of Results
  • Tandem Mass Spectrometry* / standards

Substances

  • Antimalarials
  • ZY-19489